These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37296430)

  • 1. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
    Thorn JC; Turner EL; Walsh EI; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM
    BMC Health Serv Res; 2023 Jun; 23(1):610. PubMed ID: 37296430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
    JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
    Turner EL; Metcalfe C; Donovan JL; Noble S; Sterne JA; Lane JA; Avery KN; Down L; Walsh E; Davis M; Ben-Shlomo Y; Oliver SE; Evans S; Brindle P; Williams NJ; Hughes LJ; Hill EM; Davies C; Ng SY; Neal DE; Hamdy FC; Martin RM;
    Br J Cancer; 2014 Jun; 110(12):2829-36. PubMed ID: 24867688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.
    Clift AK; Coupland CA; Hippisley-Cox J
    Br J Gen Pract; 2021; 71(703):e157-e165. PubMed ID: 33431381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
    Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
    Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
    Thorn JC; Turner EL; Hounsome L; Walsh E; Down L; Verne J; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM;
    BMJ Open; 2016 Apr; 6(4):e011063. PubMed ID: 27130167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
    Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
    Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
    Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C
    BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).
    Williams NJ; Hill EM; Ng SY; Martin RM; Metcalfe C; Donovan JL; Evans S; Hughes LJ; Davies CF; Hamdy FC; Neal DE; Turner EL;
    BMC Med Res Methodol; 2015 Jan; 15():6. PubMed ID: 25613468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study.
    Clements A; Watson E; Rai T; Bukach C; Shine B; Austoker J
    BMC Fam Pract; 2007 Jun; 8():35. PubMed ID: 17593306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.
    Brett J; Watson E; Hewitson P; Bukach C; Edwards A; Elwyn G; Austoker J
    BMC Fam Pract; 2005 Jun; 6(1):24. PubMed ID: 15946386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen testing rates and referral patterns from general practice data in England.
    Moss S; Melia J; Sutton J; Mathews C; Kirby M
    Int J Clin Pract; 2016 Apr; 70(4):312-8. PubMed ID: 26987766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.
    Lewis AL; Young GJ; Selman LE; Rice C; Clement C; Ochieng CA; Abrams P; Blair PS; Chapple C; Glazener CM; Horwood J; McGrath JS; Noble S; Taylor GT; Lane JA; Drake MJ
    Health Technol Assess; 2020 Sep; 24(42):1-122. PubMed ID: 32902375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.